Greg Gardiner

Bio

Greg serves as an advisor to Yale University’s Office of Cooperative Research (OCR), of which he was Managing Director for three years, and has held an adjunct faculty position at the Yale School of Medicine. He is a director of a number of biotech companies, including Elm Street portfolio companies Affomix Corporation and Advanced Orthopedic Technologies, Inc. Greg is Chairman of the Board of HistoRx and a consultant and advisor to several investment funds and pharmaceutical and biotech companies. Prior to the OCR, Dr. Gardiner was Group Director of R&D Operations, Pfizer Central Research, where he designed and implemented Pfizer’s external biotechnology strategy. Dr. Gardiner also participated in the management of Pfizer’s worldwide drug discovery program, and was responsible for the scientific evaluation of licensing candidates including Lipitor, Celebrex, and Aricept. Greg represents Elm Street on the boards of Affomix and Advanced Orthopedic Technologies. Dr. Gardiner received a Ph.D. in Physical Chemistry from Fordham University and was a Sterling Fellow in Chemistry at Yale.